david mazzo  aeterna zentaris inc  zoominfocom david j mazzo ba hons bsc hons msc phd executive profile  biography  bloomberg july    pm et biotechnology company overview of caladrius biosciences inc snapshotpeople  overviewboard memberscommittees executive profile david j mazzo ba hons bsc hons msc phdchief executive officer president and director caladrius biosciences incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationshipsas of fiscal year  background dr david j mazzo also known as dave ba hons bsc hons msc phd has been the chief executive officer of caladrius biosciences inc formerly neostem inc since january   and also its president since march   dr mazzo served as the president and chief executive officer of chugai usa inc he served as the chief executive officer of regado biosciences inc from august  to october   he served as the president at regado biosciences  inc since august  he served as the president and chief executive officer of chugai pharma usa llc the us subsidiary of chugai pharmaceutical ltd of japan since april  he served as the president and chief executive officer of aeterna zentaris inc from april   to april  prior to chugai dr mazzo served in management positions in several international pharmaceutical companies served as senior vice president of global development operations at the scheringplough research institute and as senior vice president and global head pharmaceutical development at hoechst marion roussel he is a pharmaceutical executive and strategic leader with broad technical and managerial experience gained from working in a variety of multicultural and multilingual environments in the usa canada europe and asia he has spent more than  years in the pharmaceutical industry and is recognized for his leadership and strong strategic scientific and regulatory expertise he has broad experience working in a variety of multicultural environments in the usa europe and asia where he amassed a track record of successful global product development registration and launch he has occupied positions of increasing responsibility with merck baxter rhonepoulenc rorer hoechst marion roussel and scheringplough where he was involved with the launch of clarinex tm nasonextm asmanex twisthalertm pegintrontm pegintron redipentm and zetiatm through his multiple assignments and many accomplishments he has acquired a thorough understanding of the drug development process from discovery to manufacturing and launch in his previous position as the senior vice president of development operations for the scheringplough research institute he led an organization of approximately  employees spanning three countries dr mazzo has been the nonexecutive chairman of psivida corp since january   he serves as the nonexecutive chairman of psivida us inc he has been a director of caladrius biosciences inc since january   he has been a nonexecutive director of psivida ltd of perth australia since july   he has been a nonexecutive director of psivida corp since july   he served as a director of regado biosciences inc from august  to october   he served as a director of aeterna zentaris inc from august   to april  he served as a director of avanir pharmaceuticals inc from july   to january   dr mazzo holds bachelor of arts degree in the honors program interdisciplinary humanities and a bachelor of science degree in chemistry from villanova university in addition dr mazzo received his master of science degree in chemistry and his phd degree in analytical chemistry from the university of massachusetts amherst he was also a research fellow at the ecole polytechnique federale de lausanne switzerlandread full background corporate headquarters  allen roadbasking ridge new jersey united statesphone fax  board members memberships nonexecutive chairmanpsivida us incpresentnonexecutive chairmanpsivida corppresentchief executive officer president and directorcaladrius biosciences inc education ms university of massachusettsphd university of massachusettsba villanova universitybs villanova university other affiliations avanir pharmaceuticals incaeterna zentaris incpsivida us incuniversity of massachusettsvillanova universitychugai usa incpsivida corpregado biosciences incchugai pharma usa llc annual compensation salarybonustotal annual compensation stocks options restricted stock awardsall other compensationexercisable optionsunexercisable optionstotal number of options total compensation total annual cash compensationtotal short term compensationother long term compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationnamepositioncompanycompensationxiaochun xu chairman of board and interim chief executive officercesca therapeutics incmarc h hedrick mdchief executive officer president  directorcytori therapeutics inckmichael tomas chief executive officer president chief financial officer and directorus stem cell incmandrey semechkin phdcochairman  chief executive officer international stem cell corporationkmark r weinreb mschairman chief executive officer and presidentbiorestorative therapies inckcompensation as of fiscal year  sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact caladrius biosciences inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close neostem strengthens executive management with appointments of david j mazzo phd as chief executive officer and robert s vaters as president and chief financial officer and elects robin smith md to executive chair of the board  caladrius neostem strengthens executive management with appointments of david j mazzo phd as chief executive officer and robert s vaters as president and chief financial officer and elects robin smith md to executive chair of the board  neostem strengthens executive management with appointments of david j mazzo phd as chief executive officer and robert s vaters as president and chief financial officer and elects robin smith md to executive chair of the board january   january   – neostem inc nasdaqnbs a leader in the development and manufacturing of cell therapy products and regenerative medicine today announced the appointments of david j mazzo phd as chief executive officer ceo and robert s vaters as president and chief financial officer cfo both dr mazzo and mr vaters will also serve as directors of the corporation simultaneously robin smith md has been elevated to the position of executive chair of the board of directors “we are committed to increasing shareholder value and believe these management changes will drive an evolution of our corporate strategy and be the first step in the next phase of the company’s growth” said dr smith executive chair of the board “the complementary leadership and technical skills of dr mazzo and mr vaters are expected to accelerate our clinical programs towards commercialization enhance business development efforts secure a global manufacturing footprint and provide commercial capacity for our clients with  world class quality and reliability these efforts as part of a continued focus on pursuing broader strategic opportunities for our latestage platform technologies are expected to increase the franchise value of our pipeline” dr mazzo brings to neostem over  years of international experience in the biotech and pharmaceutical industry most recently as ceo of regado biosciences he created and led the smallest team ever to successfully design and execute a cardiovascular megatrial prior to regado dr mazzo was chief executive officer of aeterna zentaris a multinational biopharmaceutical company focused on development of therapies in oncology and endocrinology indications previously he had served as president and ceo of chugai pharma usa llc the us subsidiary of chugai pharmaceutical co ltd of japan and a member of the roche group following his tenure at scheringplough as the senior vicepresident of development operations and  a member of the board of directors of essex chemie ag dr mazzo held positions of increasing responsibility with merck  co baxter healthcare corporation rhonepoulenc rorer and hoechst marion roussel before joining scheringplough dr mazzo currently is nonexecutive chairman of psivida inc and a director of avanir pharmaceuticals “i believe that neostem’s product platform that includes a latestage clinical pipeline presents compelling opportunities for the development of therapies for ischemic repair cancer and autoimmune disorders” said dr mazzo  “i am extremely excited to join the company at this critical time and look forward to reporting our accomplishments in the future as we achieve our strategic goals” robert s vaters comes to neostem from carob investments a strategic acquisition and investor consulting firm where he was a managing partner from  to  mr vaters was president ceo and director for orthofix international nv having served as its executive vice president chief financial officer and chief operating officer from  to  he was the foundergeneral partner of medopportunity partners llc where from  to  he identified negotiated and closed on middle market healthcare buyouts and growth equity investments specializing in pharmaceutical medical device biologic medical technology and specialty health care service industries prior to that he was executive vice president strategy and corporate development for inamed corporation a global healthcare company “after  years of financial corporate strategy investment deal making and capitalraising experience i look forward to contributing to neostem’s value with the goal of setting an industry standard for financial performance and elevating the company to the next plateau of growth while attracting a greater institutional investor base” stated mr vaters about neostem inc neostem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent treat or cure disease by repairing and replacing damaged or aged tissue cells and organs and restoring their normal function the combination of a rich therapeutics pipeline and externally recognized inhouse manufacturing expertise has created an organization with unique capabilities for cost effective and accelerated product development wwwneostemcom forwardlooking statements this press release contains forwardlooking statements within the meaning of the private securities litigation reform act of  forwardlooking statements reflect management’s current expectations as of the date of this press release and involve certain risks and uncertainties forwardlooking statements include statements herein with respect to the successful execution of the company’s business strategy the company’s ability to develop and grow its business the successful development of cellular therapies with respect to the company’s research and development and clinical evaluation efforts in connection with the company’s targeted immunotherapy program ischemic repair program immune modulation program and other cell therapies the future of the regenerative medicine industry including whether a large commercial market ever develops and whether our clients receive necessary regulatory approval to market their products and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the company’s contract development and manufacturing business the company’s actual results could differ materially from those anticipated in these forwardlooking statements as a result of various factors factors that could cause future results to materially differ from the recent results or those projected in forwardlooking statements include the “risk factors” described in the company’s annual report on form k filed with the securities and exchange commission “sec” on march   the company’s current report on form k filed with the sec on may   and in the company’s other periodic filings with the sec the company’s further development is highly dependent on future medical and research developments and market acceptance which is outside of its control management team  caladrius management team david j mazzo phd president chief executive officer and director biodavid j mazzo was appointed as caladrius chief executive officer and as a member of our board on january   in addition dr mazzo was appointed as president of the company in march  dr mazzo brings to the company over  years of experience in the pharmaceutical industry prior to joining caladrius dr mazzo served from august  to october  as chief executive officer and as a member of the board of directors of regado biosciences inc a nasdaqlisted biopharmaceutical company focused on the development of novel antithrombotic drug systems for acute and subacute cardiovascular indications prior to his leading regado from march  to april  dr mazzo was president chief executive officer and a director of æterna zentaris inc a publicly held international biopharmaceutical company from  until  dr mazzo served as president chief executive officer and a director of chugai pharma usa llc a biopharmaceutical company which was the us subsidiary of chugai pharmaceutical co ltd of japan dr mazzo has also held senior management and executive positions in research and development and was a director of the essex chimie european subsidiary at scheringplough corporation a publicly held pharmaceutical company that was subsequently acquired by merck  co inc hoechst marion roussel inc the us subsidiary of hoechst ag which was subsequently acquired by sanofi a multinational pharmaceuticals company and rhonepoulenc rorer inc a subsidiary of rhonepoulene sa a french pharmaceuticals company which was subsequently acquired by hoechst ag he also previously served on the board of avanir pharmaceuticals inc a biotechnology company which was sold to otsuka holdings in  he currently serves on the board of directors of psivida corp a publicly held biopharmaceutical company in the role of nonexecutive chairman dr mazzo earned a ba in the honors program interdisciplinary humanities and a bs in chemistry from villanova university in addition dr mazzo received his ms in chemistry and his phd degree in analytical chemistry from the university of massachusetts amherst he was also a research fellow at the ecole polytechnique federale de lausanne switzerland joseph talamo senior vice president and chief financial officer biojoseph talamo was promoted to senior vice president and chief financial officer in october  from his previous role when he joined caladrius in  as the corporate controller and chief accounting officer he is a versatile finance executive with leadership experience in publiclytraded development and commercialstage companies along with a strong background in sec compliance he has led companywide forecasting planning and analysis activities including for ma and has had extensive experience with integrating transactions and raising capital at caladrius mr talamo has been responsible for numerous financial functions including sec reporting forecasting planning and analysis cash management and accounting prior to joining caladrius from  to  mr talamo held various senior positions at osi pharmaceuticals inc “osi” a publiclytraded biopharmaceutical company focused on discovering developing and commercializing products for the treatment of cancer diabetes and obesity and most recently served as its vice president and corporate controller from  to  and its corporate controller from  to  while at osi mr talamo helped build the accounting and finance infrastructure to support the clinical development and commercial launch of tarceva® osis targeted therapy approved for the treatment of patients with nonsmall cell lung cancer and pancreatic cancer prior to osi mr talamo worked at bristolmyers squibb from  to  in the financial reporting and consolidations group and at kpmg from  to  in the health care and life sciences audit group mr talamo has served as treasurer of the stem for life foundation a public charity dedicated to raising awareness about adult stem cells and their therapeutic promise since  mr talamo also served as treasurer of the osi pharmaceuticals foundation from  to  mr talamo received a bba in accounting from hofstra university in  and an mba in finance from hofstra university in  mr talamo is a certified public accountant in the state of new york douglas w losordo md facc faha senior vice president clinical medical and regulatory affairs and chief medical officer bio dr losordo was appointed chief medical officer of the company effective august   dr losordo served from  to  as a member of the scientific advisory board of caladrius prior to his appointment as the company’s chief medical officer dr losordo served as vice president new therapies development regenerative medicine and baxter ventures at baxter international from october  through february  he is an adjunct professor of medicine at northwestern university in chicago illinois from  through  dr losordo was the director of the feinberg cardiovascular research institute and the eileen m foell professor of heart research at northwestern university’s school of medicine and director of the program in cardiovascular regenerative medicine at northwestern memorial hospital from  through  he was a professor of medicine at tufts university school of medicine and chief of cardiovascular research at st elizabeth’s medical center in boston he is boardcertified in internal medicine cardiovascular disease and interventional cardiology dr losordo’s major research interests encompass angiogenesisvasculogenesis progenitoradult stem cells tissue repairregeneration and vascular biology he received his md from the university of vermont dr losordo has engaged in careerlong efforts to develop novel therapeutics and as a scientist he obtained over  million in national institutes of health funding for discovering and developing new therapeutic concepts in the laboratory providing the basis for clinical studies he has led first in human studies in multiple gene and adult stem cell therapies in patients with cardiovascular diseases including therapies now in phase  testing he is a highly sought after speaker having given over  international lectures he has served as an associate editor of circulation research the basic science journal of the american heart association and serves on the editorial boards of a number of scientific journals since  he has served on the scientific advisory board of the stem for life foundation a public charity devoted to accelerating development of cell therapies todd girolamo jd general counsel and corporate secretary biotodd girolamo joined caladrius in  he is a seasoned attorney specializing in healthrelated products and businesses as a member of the caladrius senior management team mr girolamo has been responsible for managing all legal aspects of the company’s research and development pipeline from preclinical research to multinational pivotal clinical trials including academic and corporate collaborations he has been responsible for the company’s licensing activities the strategy maintenance and prosecution of the company’s extensive global patent estate and the management of all litigation involving the company and its subsidiaries mr girolamo began his legal career as an associate at cahill gordon  reindel and he concluded his tenure in private practice at reid  priest where he gained expertise as a general commercial litigator practicing in the areas of intellectual property securities law employment law and bankruptcy in addition to over a decade of experience as both corporate counsel and private practitioner mr girolamo spent  years on wall street where he specialized in therapeutic healthcare equity securities at oppenheimer  co cibc world markets leerink swann  company and summer street research partners mr girolamo received a bachelor of arts from harvard college juris doctor from the university of pennsylvania law school and master of business administration from columbia business school raj prabhakar senior vice president business development biosince  raj prabhakar has served as head of business development and reports directly to ceo dr david mazzo raj leads all outlicensing inlicensing ma and partnership opportunities and serves on the executive committee of caladrius biosciences current priorities include global partnerships for each of the investigational clinical candidates in immuneoncology immunemodulation and cardiovascular indications in addition to manufacturing jvs and acquisitions prior to caladrius biosciences raj prabhakar served as vice president and head of business development for celsion corporation from  to  including the acquisition of egen inc a gene therapy and delivery company at celsionegen he led partnerships for immuneoncology gene therapy small molecules new formulations and oligonucleotide delivery for dna rna and gene editing candidates raj has particular transaction experience in asiapacific with leading pharmaceutical companies in japan and china prior to celsion raj was employed at path global vaccine development group protiveris osiris therapeutics and harvard medical schoolbrigham  women’s hospital in multiple corporate development business development commercialization and research roles raj holds an mba from the harvard business school and dual bachelors of science degrees in biology and mechanical engineering from the massachusetts institute of technology david schloss vice president human resources biodavid schloss a senior human resources executive and former attorney with over  years of leadership experience joined caladrius biosciences in  as vice president human resources at the company mr schloss is responsible for the development and delivery of compensation benefits organizational design and development recruitment and employee relations mr schloss comes to caladrius formerly neostem with a strong resume of experience in the pharmaceutical and biotechnology industries prior to joining caladrius he served as svp human resources with plus diagnostics acquired by miraca life sciences prior to plus diagnostics mr schloss led human resources for orapharma from   a private equity owned specialty pharmaceutical company focused on oral health care mr schloss helped grow the company and was instrumental in its acquisition and integration by valeant pharmaceuticals international prior to orapharma from  mr schloss was vice president human resources for eurand pharmaceuticals a publicly traded specialty pharmaceutical company based in italy that develops manufactures and commercializes pharmaceutical and biopharmaceutical products while with eurand mr schloss helped build the commercial organization that launched zenpep® for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis eurand was acquired by aptalis in  from  mr schloss led human resources for imclone systems a fully integrated global biopharmaceutical company engaged in the development and commercialization of a portfolio of targeted biological oncology treatments he also led imclone system’s human resources through its acquisition by eli lilly in  additionally mr schloss spent  years with glaxosmithkline in a number of senior level hr roles across the us and internationally before beginning his career in human resources mr schloss was an attorney practicing in the representation of management in all phases of labor relations and employment law he earned a ba from clark university and a jd from the university of miami school of law he currently serves on the pennsylvania advisory board of the devereux foundation a leading nonprofit behavioral health organization that provides support and services to children and adults with intellectual emotional developmental and behavioral challenges greg berkin vice president information technology bioms computer sciencecomputer forensics fairleigh dickinson university greg berkin joined caladrius in january  since that time greg has been responsible for transforming external it support into an internal team working as a highly efficient operating unit across all five caladrius and pct sites he also manages all groups within it networking pc applications business solutions and telecom before joining caladrius greg held director and management roles in it at companies including regado biosciences aeterna zentaris and chugai pharma usa greg has more than  years in the technical profession with  years of unparalleled managerial experience specializing in production systems network engineering facility operations project management hybrid cloudcomputing and cybersecurity access to this page has been denied please verify you are a human please click i am not a robot to continue access to this page has been denied because we believe you are using automation tools to browse the website this may happen as a result of the following javascript is disabled or blocked by an extension ad blockers for example your browser does not support cookies please make sure that javascript and cookies are enabled on your browser and that you are not blocking them from loading reference id abdbeecfbaff powered by perimeterx  inc access to this page has been denied please verify you are a human please click i am not a robot to continue access to this page has been denied because we believe you are using automation tools to browse the website this may happen as a result of the following javascript is disabled or blocked by an extension ad blockers for example your browser does not support cookies please make sure that javascript and cookies are enabled on your browser and that you are not blocking them from loading reference id adadbebbbcbdbbece powered by perimeterx  inc access to this page has been denied please verify you are a human please click i am not a robot to continue access to this page has been denied because we believe you are using automation tools to browse the website this may happen as a result of the following javascript is disabled or blocked by an extension ad blockers for example your browser does not support cookies please make sure that javascript and cookies are enabled on your browser and that you are not blocking them from loading reference id aebaddbeaddf powered by perimeterx  inc david j mazzo caladrius biosciences inc chief executive officer  redbooks brands marketers agencies search less sell more    sign in get a free trial    contact us   david j mazzo chief executive officer caladrius biosciences inc email realtime sales trigger feed  generated by redbooks machine learning and natural language processing technology tracking  news sources to aggregate all new executives jobrole changes and news on decision makers brands and agencies in the mediamarketing industry this sales feed is for david j mazzo at caladrius biosciences inc david j mazzo works as chief executive officer  acting in a executive management role  caladrius biosciences inc is a leader in pharmaceuticals  health care products  redbooks tracks personnel changes for advertisers spending over  million annually for more executive management leads or mediamarketing prospecting automation start a free trial now recent related news  caladrius biosciences announces that  of subjects have been treated in the phase  clinical trial of clbs for type  diabetes caladrius biosciences inc nasdaqclbs caladrius or the company a development stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications announces that  of subjects have been treated in the sanford project trex study a prospective randomized placebocontrolled doubleblind phase  clinical trial to evaluate the safety and efficacy of the companys clbs as a treatment for recentonset type  diabetes td  people in this article david j mazzo  caladrius biosciences joins russell microcap index june   caladrius biosciences inc nasdaqclbs caladrius or the company a cellular therapeutics development company with a pipeline focused on autoimmune disease and select cardiovascular indications announces today that the company has joined the russell microcap index as part of the russell indexes annual reconstitution effective after the us financial market opens todaymembership in the russell microcap index which remains in place for one year means automatic inclusion in the appropriate growth and value style indexes  people in this article david j mazzo learn more about david j mazzo and  key contacts   create targeted lead lists   gain insider knowledge with advanced machine  learning   realtime verified contact info enter work email please enter email address please enter valid email address learn more about david j mazzo and  key contacts first name  please enter first name last name  please enter last name company name  please enter company name email  phone  please enter phone number please enter  digits number what industry are you in    please select one the categories below please enter value for the industry  media sales  production  adtechmartech  sponsorship sales   agency new business   other what is your role    please select one the categories below please enter value for the role   csuite   vpmanager   sales rep   other thank you for registering for a free redbookscom trial we are processing your request and will be in touch shortly to get you started for immediate assistance please call us at   or email us at inforedbookscom home learn more free trial features ad think events thought leadership events top advertiser directory top agency directory add your agency update your agency agency showcase advertising associations creative spotlight services and suppliers about us blog contact us jobs terms  conditions privacy policy customer support   connect with us copyright   red books llc all rights reserved david j mazzo  basking ridge nj  intelius sign in we found david j mazzo in basking ridge nj david j mazzo intelius found that david j mazzo is a male between  and  years old from basking ridge nj we have connected them to  addresses  phones and  relatives or associates also known as david john mazzo get report now age david j mazzo is in his s david has lived in basking ridge nj lake zurich il fort washington pa davids relatives cheryl mazzo t thorry rocco mazzo frances mazzo david j mazzo zodiac signsagittarius gendermale professional status chief executive officer  director at caladrius biosciences inc get report now want to know more about david get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about david or use our people search engine to find others get background check on david j mazzo get a criminal check on david j mazzo get a public record report on david j mazzo get a people search report on david j mazzo david j mazzos contact information known cities lived in find out where david j mazzo has lived as well as david j mazzos phone numbers and email addresses david j mazzo has lived in  states new jersey address for david j mazzo  m v b basking ridge nj has lived in basking ridge nj lake zurich il get full address report phone numbers associated with david j mazzo    bernardsville nj    basking ridge nj    berkeley heights nj get full phone report email addresses associated with david j mazzo docom docom dmcom get email report david j mazzos education information known schools attended learn about david j mazzos academic history find out which schools david j mazzo attended the dates attended as well as the degrees david j mazzo received the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act david j mazzo has attended  schools university of massachusetts amherst  –  david j mazzo has a phd in chemistry university of massachusetts amherst  –  david j mazzo has a phd chemistry in chemistry villanova university  –  david j mazzo has a bs and ba in chemistry and honors villanova university  –  david j mazzo has a bs and ba chemistry and honors in chemistry and honors david j mazzos professional information information regarding david j mazzos professional history find out previous places david j mazzo has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act david j mazzo has worked at  places company caladrius biosciences inc title chief executive officer  director company regado biosciences  inc title president and chief executive officer david j mazzos experience title chief executive officer  director company caladrius biosciences inc job details company size  mil to less than  mil  employee range  to less than  title president and chief executive officer company regado biosciences  inc job details company size unknown  employee range  to less than  regado biosciences inc is a biopharmaceutical company focused on the development of novel firstinclass actively controllable antithrombotic drug systems for acute and subacute cardiovascular indications regado is pioneering the development of twocomponent drug systems consisting of a therapeutic aptamer and its specific active control agent the companys lead product candidate reg is a twocomponent system consisting of pegnivacogin an anticoagulant aptamer specifically targeting coagulation factor ixa and its complementary oligonucleotide active control agent anivamersen reg is currently being evaluated in the regulatepci trial a worldwide phase  study enrolling  patients with acute coronary syndromes acs undergoing a percutaneous coronary intervention pci a hospitalbased procedure used to mechanically open or widen obstructed coronary arteries regados actively controllable product candidates have the potential to improve patient outcomes enhance the patient experience and reduce overall treatment costs additional professional information on david j mazzo see david j mazzos linkedin profile david j mazzos social network and potential email matches find out potential social network profiles and potential email usernamed for david j mazzo david j mazzos known social networks and potential email matches find all of david j mazzos social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches david mazzo username matches davidmazzo mazzodavid davidmazzo mazzodavid davidmazzo mazzodavid davidmazzo mazzodavid dmazzo popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches d mazzo intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here david j mazzo  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors david j mazzo check out list of companies and businesses related to david j mazzo find out david j mazzo address and contact details view other people related to david j mazzo  coworkers colleagues companions etc address  mountain view boulevard co regado biosciences inc basking ridge  nj companies related to david j mazzo cikcompany namepositioncompany addresstobira therapeutics incchief executive officer  gateway blvd suite  south san francisco  david j mazzo on the web persons related to david j mazzo  tobira therapeutics incnamepositioncityplc actavisparsippanyallergan holdco us incirvinegopka antonbasking ridgeclark bbasking ridge fcpr biodiscovery owner parisbiotechnology value fund ii lpchicagobiotechnology value fund l pchicagobiotechnology value fund l pchicagojames c blair owner princetoncarol l brosgartdirector south san franciscobvf incilchicagobvf partners l pil chicagocourts chrisbasking ridgeb jefferson clarkdirector basking ridgeb jefferson clarkdirector basking ridgeb jefferson clarkdirector basking ridgejeffrey h cooperdirector novatochristopher courtsvice president of finance basking ridgechristopher courtsvice president of finance basking ridgemazzo davidbasking ridgepodlesak dennisbasking ridgeassociates domain owner princetondomain parters vii l p owner princetondomain partners vi lp owner princetonbrian h doveybrian h dovey owner princetondp vi associates lp owner princetondp vii associates lp owner princetonde rothschild investment partners edmondparisr don elseysr vpchief financial officer basking ridger don elseysr vpchief financial officer basking ridgelaurent fischerchief executive officer watertownfrazier healthcare v lp owner seattleandrew j fromkindirector basking ridgeandrew j fromkindirector basking ridgedrew j fromkindirector newtonalexander r giaquintocco and svp of reg affairs basking ridgealexander r giaquintocco svp of reg affairs basking ridgeanton gopkadirector basking ridgeanton gopkadirector basking ridgeanton gopkadirector basking ridgebrian k halakprincetonpatrick j herondirector palo altoclark jeffbasking ridgehelen jenkinschief operating officer south san franciscotreu jessebasking ridgekim p kamdarprincetonrobert a kierlin owner winonarobert a kierlin owner winonamark n lampertsan franciscoeric lefebvrechief medical officer south san franciscopierre legaultdirector berkeley heightspierre legaultdirector basking ridgepierre legaultbasking ridgedavid j mazzopresident and ceo basking ridgedavid j mazzochief executive officer basking ridgeellen mcdonaldsvp  chief business officer basking ridgegwen a melincoffdirector south san franciscomichael mendelsohnbasking ridgemichael mendelsohndirector basking ridgemichael mendelsohndirector basking ridgemichael a metzgerpresident and coo basking ridgemichael a metzgerpresident  ceo basking ridgemendelsohn michaelbasking ridgemetzger michaelbasking ridgep sherrill neffdirector basking ridgep sherrill neffphiladelphiap sherrill neffdirector philadelphiaas novo owner bagsvaerdneff pbasking ridgechristopher peetzchief financial officer south san francisconicholas j pelliccionesr vp of regulatory affairs basking ridgepentwater capital management lp owner chicagolegault pierrebasking ridgedennis podlesakdirector san diegodennis podlesakdirector basking ridgedennis podlesakdirector basking ridgedennis podlesakdirector basking ridgequaker bio ventures lp owner philadelphiaquaker bioventures capital lpphiladelphiawishiewski raphaelbasking ridgewisniewski raphaelbasking ridgeinvestments sarl rmiluxembourginvestments sarl rmi owner moscowchristopher paul rusconidurhamchristopher paul rusconichief scientific officer basking ridgechristopher paul rusconichief scientific officer basking ridgerusnanomedinvest llcmoscowrusnanomedinvest llcmoscowsapphire acquisition corpparsippanykathleen k schoemaker owner princetonnimesh shahprincetonjesse i treudirector princetonnicole vitullorichmondnicole vitullo owner princetoneckard weberdirector south san franciscoraphael wisniewskidirector basking ridgeraphael wisniewskidirector basking ridgesteven zelenkofskesvp  chief medical officer basking ridgesteven zelenkofskesvp  chief medical officer basking ridge insider trading  mazzo david j  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  mazzo david j select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing purchase  pm caladrius biosciences inc clbs mazzo david jchief executive officerdirector    direct view stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing option award  pm  psivida corp psdv mazzo david jdirector   direct view tax withholding  pm nana caladrius biosciences inc clbs mazzo david jchief executive officerdirector   direct view option award  pm  caladrius biosciences inc clbs mazzo david jchief executive officerdirector   direct view tax withholding  pm nana caladrius biosciences inc clbs mazzo david jchief executive officerdirector   direct view tax withholding  pm nana caladrius biosciences inc clbs mazzo david jchief executive officerdirector   direct view option award  pm nana caladrius biosciences inc clbs mazzo david jchief executive officerdirector   direct view tax withholding  pm nana caladrius biosciences inc clbs mazzo david jchief executive officerdirector   direct view option award  pm na caladrius biosciences inc clbs mazzo david jchief executive officerdirector   direct view option award  pm  psivida corp psdv mazzo david jdirector   direct view option award  pm nana neostem inc nbs mazzo david jchief executive officerdirector   direct view   secformcom all rights reserved archives        mon  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  neostem inc strengthens executive management with appointments of david j mazzo phd as chief executive officer and robert s vaters as president and employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       neostem inc strengthens executive management with appointments of david j mazzo phd as chief executive officer and robert s vaters as president and chief financial officer and elects robin smith md to executive chair of the board tweet   am new york jan   globe newswire  neostem inc nasdaqnbs a leader in the development and manufacturing of cell therapy products and regenerative medicine today announced the appointments of david j mazzo phd as chief executive officer ceo and robert s vaters as president and chief financial officer cfo both dr mazzo and mr vaters will also serve as directors of the corporation simultaneously robin smith md has been elevated to the position of executive chair of the board of directors we are committed to increasing shareholder value and believe these management changes will drive an evolution of our corporate strategy and be the first step in the next phase of the companys growth said dr smith executive chair of the board the complementary leadership and technical skills of dr mazzo and mr vaters are expected to accelerate our clinical programs towards commercialization enhance business development efforts secure a global manufacturing footprint and provide commercial capacity for our clients with world class quality and reliability these efforts as part of a continued focus on pursuing broader strategic opportunities for our latestage platform technologies are expected to increase the franchise value of our pipeline dr mazzo brings to neostem over  years of international experience in the biotech and pharmaceutical industry most recently as ceo of regado biosciences he created and led the smallest team ever to successfully design and execute a cardiovascular megatrial prior to regado dr mazzo was chief executive officer of aeterna zentaris a multinational biopharmaceutical company focused on development of therapies in oncology and endocrinology indications previously he had served as president and ceo of chugai pharma usa llc the us subsidiary of chugai pharmaceutical co ltd of japan and a member of the roche group following his tenure at scheringplough as the senior vicepresident of development operations and a member of the board of directors of essex chemie ag dr mazzo held positions of increasing responsibility with merck  co baxter healthcare corporation rhonepoulenc rorer and hoechst marion roussel before joining scheringplough dr mazzo currently is nonexecutive chairman of psivida inc and a director of avanir pharmaceuticals i believe that neostems product platform that includes a latestage clinical pipeline presents compelling opportunities for the development of therapies for ischemic repair cancer and autoimmune disorders said dr mazzo i am extremely excited to join the company at this critical time and look forward to reporting our accomplishments in the future as we achieve our strategic goals robert s vaters comes to neostem from carob investments a strategic acquisition and investor consulting firm where he was a managing partner from  to  mr vaters was president ceo and director for orthofix international nv having served as its executive vice president chief financial officer and chief operating officer from  to  he was the foundergeneral partner of medopportunity partners llc where from  to  he identified negotiated and closed on middle market healthcare buyouts and growth equity investments specializing in pharmaceutical medical device biologic medical technology and specialty health care service industries prior to that he was executive vice president strategy and corporate development for inamed corporation a global healthcare company after  years of financial corporate strategy investment deal making and capitalraising experience i look forward to contributing to neostems value with the goal of setting an industry standard for financial performance and elevating the company to the next plateau of growth while attracting a greater institutional investor base stated mr vaters about neostem inc neostem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent treat or cure disease by repairing and replacing damaged or aged tissue cells and organs and restoring their normal function the combination of a rich therapeutics pipeline and externally recognized inhouse manufacturing expertise has created an organization with unique capabilities for cost effective and accelerated product development wwwneostemcom forwardlooking statements this press release contains forwardlooking statements within the meaning of the private securities litigation reform act of  forwardlooking statements reflect managements current expectations as of the date of this press release and involve certain risks and uncertainties forwardlooking statements include statements herein with respect to the successful execution of the companys business strategy the companys ability to develop and grow its business the successful development of cellular therapies with respect to the companys research and development and clinical evaluation efforts in connection with the companys targeted immunotherapy program ischemic repair program immune modulation program and other cell therapies the future of the regenerative medicine industry including whether a large commercial market ever develops and whether our clients receive necessary regulatory approval to market their products and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the companys contract development and manufacturing business the companys actual results could differ materially from those anticipated in these forwardlooking statements as a result of various factors factors that could cause future results to materially differ from the recent results or those projected in forwardlooking statements include the risk factors described in the companys annual report on form k filed with the securities and exchange commission sec on march   the companys current report on form k filed with the sec on may   and in the companys other periodic filings with the sec the companys further development is highly dependent on future medical and research developments and market acceptance which is outside of its control contact investor contact lifesci advisors llc hans vitzthum managing director phone  email hanslifesciadvisorscom media contact neostem inc eric powers manager of communications and marketing phone  email epowersneostemcom help employers find you check out all the jobs and post your resume read at biospacecom related news neostem incs stem cell therapy fails midstage heart attack study bungling of virus prompts hiring of cdc safety chief neostem inc provides further information regarding the design of the phase  preserve ami clinical trial we made a list and checked it twice biospace dhx’s naughty and nice neostem inc announces initial positive data from phase  preserve ami clinical trial conkwest nabs  million and snags biotech billionaire as cochairman of the board neostem incs subsidiary progenitor cell therapy earns aabb reaccreditation for its allendale nj manufacturing facility exsarepta therapeutics srpt exec to head massachusetts startup checkmate pharmaceuticals neostem inc announces usan approval of generic name eltrapuldencelt for investigational patientspecific targeted cancer immunotherapy novo nordisk as nvo already seeking successor for ceo that will most likely step down in  please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • caladrius biosciences formerly known as neostem inc   • biotechpharma  personnel